Intercell's Partner Merck Initiates Phase II Study of Bacterial Vaccine
Posted on: Thursday, 28 August 2008, 09:01 CDT
Austria-based biotechnology company Intercell has announced that its collaborator Merck & Co has initiated a Phase II clinical trial of V710, an investigational vaccine for the prevention of Staphylococcus aureus infections.
This randomized double blind, placebo controlled study aims to evaluate the safety and immunogenicity of the vaccine candidate in patients with end-stage kidney disease on hemodialysis. This trial start follows the initiation of a separate Phase II trial in December 2007.
The Staphylococcus aureus vaccine candidate is based on a conserved protein antigen discovered by Intercell and licensed to Merck & Co in 2004 on an exclusive world wide basis.
Merck is responsible for clinical development, manufacturing and marketing. Intercell is eligible to receive milestone payments and royalties on future net sales.
Gerd Zettlmeissl, CEO of Intercell, said: "We are very pleased that our strategic partner Merck has chosen to initiate a further Phase II clinical trial. We look forward to continued progress of the program building on clinical data obtained so far."
Source: Datamonitor
Related Articles
- Reportlinker Adds Innovations and Trends in Clinical Trials: Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
- Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
- Intercell Completes Phase I Influenza Vaccine Trial
- FDA Lifts Clinical Hold on Vion's Phase III Trial of Leukemia Drug
- Emergent BioSolutions Announces That the Final Phase II Clinical Study Results for Typhoid Vaccine Reaffirms Clinical Endpoints Met; Immune Response Seen in 97% of Treated Subjects
- Inovio Biomedical Partner Tripep Files Application for Phase I Clinical Study of Hepatitis C DNA Vaccine
- FDA Advisory Committee Votes Unanimously That Clinical Data Support the Efficacy and Safety of GARDASIL(R), Merck's Investigational Cervical Cancer Vaccine; If Approved, GARDASIL Will Be the First Cervical Cancer Vaccine in the U.S.
- Intracel and FDA Agree on Pivotal Phase III Clinical Protocol for Colon Cancer Vaccine
- China Approves Clinical Study of New SARS Vaccine
- Altus Pharmaceuticals Announces Completion of Clinical Testing in the Phase I Study of ALTU-238 - a Long-Acting Crystalline Formulation of Human Growth Hormone
 |
 |
User Comments (0)
RSS Feeds